Open AccessThe SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
Author(s) -
Roselle Herring,
Fariba ShojaeeMoradie,
Mary Stevenage,
Iain Parsons,
Nicola Jackson,
Jeewaka Mendis,
Benita Middleton,
A. Margot Umpleby,
Barbara A. Fielding,
Melanie J. Davies,
David RussellJones
Publication year - 2022
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc21-2043
Subject(s) - dapagliflozin , ketogenesis , lipolysis , endocrinology , medicine , glucagon , type 2 diabetes , diabetes mellitus , excretion , chemistry , ketone bodies , insulin , metabolism , adipose tissue
To investigate the mechanism for increased ketogenesis following treatment with the SGLT2 inhibitor dapagliflozin in people with type 2 diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom